HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINE COMPOSITIONS
A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.
1 . A composition comprising at least a one peptide, the peptide comprising an isolated, prepared epitope consisting of a sequence selected from the group consisting of:
(SEQ ID NO: 1)
VLYGPDAPTV,
(SEQ ID NO: 2)
YLSGANLNV,
(SEQ ID NO: 3)
ATVGIMIGV,
(SEQ ID NO: 4)
LLPENNVLSPV,
(SEQ ID NO: 5)
KLCPVQLWV,
(SEQ ID NO: 6)
KLBPVQLWV,
(SEQ ID NO: 7)
SLPPPGTRV,
(SEQ ID NO: 8)
SMPPPGTRV,
(SEQ ID NO: 9)
KLFGSLAFV,
(SEQ ID NO: 10)
KVFGSLAFV,
(SEQ ID NO: 11)
VMAGVGSPYV,
(SEQ ID NO: 12)
ALCRWGLLL,
(SEQ ID NO: 13)
FLWGPRALV,
(SEQ ID NO: 14)
HLYQGCQVV,
(SEQ ID NO: 15)
ILHNGAYSL,
(SEQ ID NO: 16)
IMIGVLVGV,
(SEQ ID NO: 17)
KIFGSLAFL,
(SEQ ID NO: 18)
KVAELVHFL,
(SEQ ID NO: 19)
LLTFWNPPV,
(SEQ ID NO: 20)
LVFGIELMEV,
(SEQ ID NO: 21)
QLVFGIELMEV,
(SEQ ID NO: 22)
RLLQETELV,
(SEQ ID NO: 23)
VVLGVVFGI,
(SEQ ID NO: 24)
YLQLVFGIEV, and
(SEQ ID NO: 25)
YMIMVKCWMI.
2 . A composition of claim 1 , wherein the epitope is joined to an amino acid linker.
3 . A composition of claim 1 , wherein the epitope is admixed or joined to a CTL epitope.
4 . A composition of claim 1 , wherein the epitope is admixed or joined to an HTL epitope.
5 . A composition of claim 4 , wherein the HTL epitope is a pan-DR binding molecule.
6 . A composition of claim 1 , further comprising a liposome, wherein the epitope is on or within the liposome.
7 . A composition of claim 1 , wherein the epitope is joined to a lipid.
8 . A composition of claim 1 , wherein epitope is a heteropolymer.
9 . A composition of claim 1 , wherein the epitope is a homoplymer.
10 . A composition of claim 1 , wherein the epitope is bound to an HLA heavy chain, β2-microglobulin, and strepavidin complex, whereby a tetramer is formed.
11 . A composition of claim 1 , further comprising an antigen presenting cell, wherein the epitope is on or within the antigen presenting cell.
12 . A composition of claim 11 , wherein the epitope is bound to an HLA molecule on the antigen presenting cell, whereby when an A2-restricted cytotoxic lymphocyte (CTL) is present, a receptor of the CTL binds to a complex of the HLA molecule and the epitope.
13 . A composition of claim 11 , wherein the antigen presenting cell is a dendritic cell.
14 . A composition comprising one or more peptides, and further comprising at least three epitopes selected from the group consisting of:
(SEQ ID NO: 1)
VLYGPDAPTV,
(SEQ ID NO: 2)
YLSGANLNV,
(SEQ ID NO: 3)
ATVGIMIGV,
(SEQ ID NO: 4)
LLPENNVLSPV,
(SEQ ID NO: 5)
KLCPVQLWV,
(SEQ ID NO: 6)
KLBPVQLWV,
(SEQ ID NO: 7)
SLPPPGTRV,
(SEQ ID NO: 8)
SMPPPGTRV,
(SEQ ID NO: 9)
KLFGSLAFV,
(SEQ ID NO: 10)
KVFGSLAFV,
(SEQ ID NO: 11)
VMAGVGSPYV,
(SEQ ID NO: 12)
ALCRWGLLL,
(SEQ ID NO: 13)
FLWGPRALV,
(SEQ ID NO: 14)
HLYQGCQVV,
(SEQ ID NO: 15)
ILHNGAYSL,
(SEQ ID NO: 16)
IMIGVLVGV,
(SEQ ID NO: 17)
KIFGSLAFL,
(SEQ ID NO: 18)
KVAELVHFL,
(SEQ ID NO: 19)
LLTFWNPPV,
(SEQ ID NO: 20)
LVFGIELMEV,
(SEQ ID NO: 21)
QLVFGIELMEV,
(SEQ ID NO: 22)
RLLQETELV,
(SEQ ID NO: 23)
VVLGVVFGI,
(SEQ ID NO: 24)
YLQLVFGIEV, and
(SEQ ID NO: 25)
YMIMVKCWMI;
wherein each of said one or more peptides comprise less than 50 contiguous amino acids that have 100% identity with a native peptide sequence.
15 . A composition of claim 14 , wherein one peptide comprises the at least three epitopes.
16 . A composition of claim 14 , comprising at least four epitopes selected from the group of claim 14 .
17 . A composition of claim 14 , comprising at least five epitopes selected from the group of claim 14 .
18 . A composition of claim 14 , comprising at least six epitopes selected from the group of claim 14 .
19 . A composition of claim 14 , comprising at least seven epitopes selected from the group of claim 14 .
20 . A composition of claim 14 , comprising at least eight epitopes selected from the group of claim 14 .
21 - 36 . (canceled)